BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatment Three oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipeline SAN CARLOS, Calif. — BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors... The post BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts appeared first on Montreal Gazette .

Original source: Montreal Gazette